PT-141 (bremelanotide) takes a fundamentally different approach than PDE5 inhibitors like Viagra: it acts on MC3R and MC4R receptors in the hypothalamus to generate sexual desire, rather than increasing blood flow. FDA approved it as Vyleesi for hypoactive sexual desire disorder in premenopausal women — that is a real approval for a real mechanism. The "natural" framing is pure marketing. Nausea affects roughly 40% of users (serious enough that the FDA required a black box warning about nausea/vomiting), and blood pressure can drop transiently. For men, the evidence is much thinner — early Phase 2 trials for erectile dysfunction, none approved. If you have the specific condition it is approved for, it is a legitimate option with legitimate tradeoffs. Calling that "natural" is an insult to pharmacology.